Nipp 2019.

Study characteristics
Methods	Pilot randomised trial, USA.
Participants	Hospitalised patients with cancer.
Interventions	Daily symptom reports using the Edmonton Symptom Assessment System and Patient Health Questionnaire‐4 with graphical feedback including alerts to clinical team during daily rounds.    Intervention features Multiple simple feedback (one PROM at multiple times) PROM(s) used as intervention: Edmonton Symptom Assessment System and Patient Health Questionnaire‐4 Constructs measured: Symptoms Instrument categories/domains: Domain/Disease specific (cancer)   Administration features Where PROMs administered: Clinical setting (e.g. waiting room, office, etc) How administered: Self‐administered Format of PROMs questionnaire(s): Electronic   Feedback features Format of PROMs feedback: Electronic How often information fed back: Daily Who information fed back to: Clinicians Information fed back: Scores, Previous scores, Interpretation guidance, Management recommendations
Outcomes	Primary outcome: feasibility defined as >75% of patients hospitalised for 3 days or longer completing >2 symptom reports.  Secondary outcome: preliminary assessment of feasibility.
Notes	Funded by National Cancer Institute (USA), Massachusetts General Hospital Cancer Centre, and Schullen Centre for Cancer Data Analysis. The study period was not reported. The authors declared no conflicts of interest.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation using a computer.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded by design.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Unblinded by design.
Baseline outcome measurements similar	Low risk	Adjusted for within analysis.
Baseline characteristics similar	Low risk	Baseline values were similar.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention‐to‐treat analysis.
Was study protected against contamination	High risk	Chance that control arm patients can report symptoms.
Selective reporting (reporting bias)	Unclear risk	Protocol not published.